Skip to content

Study of Some Risk Factors for Developing RA

Study of Some Risk Factors for Developing Rheumatoid Arthritis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03624179
Enrollment
60
Registered
2018-08-10
Start date
2018-08-15
Completion date
2018-09-20
Last updated
2018-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

Introduction Rheumatoid arthritis (RA), a chronic autoimmune disease of unknown etiology, .If not managed early , RA can result in irreversible, painful, and disabling joint damage. RA is often diagnosed using predefined criteria that necessitate clinical, laboratory, and radiologic examinations. The prevalence of RA among adults is approximately 1-2% affecting women two to four times more often than men.Although RA risk increases with age, it can manifest at any stage of life, including childhood, adolescence, and adulthood.(1-4)( Karlson EW, Mandl LA, Hankinson SE, Grodstein F, Karlson EW, Mandl LA, Hankinson SE, Grodstein F., Karlson EW, Mandl LA, Hankinson SE, Grodstein F, Karlson EW, Mandl LA, Hankinson SE, Grodstein F) To date, a limited number of RA risk or protective factors have been identified, with genetic predisposition to autoimmune response (eg, HLA-DR4 gene) and repeated environmental exposures (eg, tobacco smoke) playing a major role.(3)(Karlson EW, Mandl LA, Hankinson SE, Grodstein F) Heritability of RA is well-established because the lifetime risk of RA and related autoimmune diseases (namely, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, Sjo¨gren's syndrome, and hypothyroidism) increases 1.5 to 3 times in children of women diagnosed with RA.

Detailed description

Patients will answer the following the questationnaire: Name age gender 1 Socio echonomic status (average salary \\year) (Education) (Job) (residence) 1. Body mass index (height\\wt2) 2. Disease duration in months. 3. Smoking (yes) (No) Passive smoker Ex smoker 4. Reproductive history: * age of menarche…. * menstrual cycle….. regular or not……. P / C * How many pregnancies…….. living. * Abortion. * patient age at first birth (….). * breast feeding…..(yes)…….(no) * use of contraceptives (yes)…pills injections IUD (N0)…… * Does patient get pregnant during disease?...(Yes)……(no)….. Does the arthritis improved (…)or got worse (…..) -flared during the purpurium.(yes) … (No) * age of menupause…. 10 Exposure to sun….(yes)…..(No) 11 -Theraputic history… (Newly diagnosed) * (Previously diagnosed), * Does the patient receiving ttt? (yes) (Steroid)……. (NSAIDS)……. (2nd line drugs) (.Methotrexat(.…), Leflonamide (….) Hydroquine(….) (NO)…….. * The study will include 100 patients fullfilling ACR 2010 * Patients well subjected to * Through clinical examination with emphysis on joints examination * venous blood sampling will withdrawn and the following investigations will be done. * Serum VIT D level * Serum calcium and phosphorus * Anti cyclic citrullinated peptide. * ESR

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* patients with rheumatoid arthritis diagnosed based on american collegue of rheumatology 2010 criteria with no history of vit D therapy

Exclusion criteria

* patients with rheumatoid arthritis on vit D supplements * patient refusal * patient not fullfill american collegue of rheumatology 2010 citeria for diagnosis pf rheumatoid arthritis

Design outcomes

Primary

MeasureTime frameDescription
vitamin D levelone monthblood sample using ELISA kits
Body mass indexone monthweight in kg/m\^2

Secondary

MeasureTime frameDescription
Anti cyclic citrullnated peptide antibodiesone monthblood sample using ELISA
Rheumatoid factor antibodyone monthblood sample

Contacts

Primary ContactEbtsam M Abd El Hakeem, MIS
smilemostafa@gmail.com01065889869
Backup ContactEL Badry I Abo Elnour, MD
aboelnour@aun.edu.eg01091131611

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026